

# Matthew R Weir

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1830663/matthew-r-weir-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

474  
papers

19,411  
citations

74  
h-index

122  
g-index

516  
ext. papers

22,650  
ext. citations

5.6  
avg, IF

6.76  
L-index

#	Paper	IF	Citations
474	KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD.. <i>American Journal of Kidney Diseases</i> , <b>2022</b> ,	7.4	1
473	Emergency Department/Urgent Care as Usual Source of Care and Clinical Outcomes in CKD: Findings From the Chronic Renal Insufficiency Cohort Study.. <i>Kidney Medicine</i> , <b>2022</b> , 4, 100424	2.8	0
472	Prediction of Incident Heart Failure in CKD: The CRIC Study.. <i>Kidney International Reports</i> , <b>2022</b> , 7, 708-719	1.1	0
471	Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials: A Review.. <i>JAMA Cardiology</i> , <b>2022</b> ,	16.2	3
470	Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2022</b> , 24, 12-20	6.7	1
469	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 36, 108101	3.2	2
468	Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 24, 230	12.3	4
467	Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes. <i>Diabetes Therapy</i> , <b>2021</b> , 12, 3167-3186	3.6	1
466	Hyperkalemia management in the emergency department: An expert panel consensus. <i>Journal of the American College of Emergency Physicians Open</i> , <b>2021</b> , 2, e12572	1.6	0
465	Effect of Levothyroxine on Kidney Function in Chronic Kidney Disease with Subclinical Hypothyroidism in US Veterans: A Retrospective Observational Cohort Study. <i>Advances in Therapy</i> , <b>2021</b> , 38, 1185-1201	4.1	2
464	Causes of Renal Allograft Injury in Recipients With Normal Donor-derived Cell-free DNA. <i>Transplantation Direct</i> , <b>2021</b> , 7, e679	2.3	2
463	The Importance of Bringing Transplantation Tolerance to the Clinic. <i>Transplantation</i> , <b>2021</b> , 105, 935-940	1.8	1
462	BLOOD PRESSURE EFFECTS OVER TIME OF BIPOLAR RADIOFREQUENCY RENAL DENERVATION IN UNTREATED HYPERTENSION. <i>Journal of Hypertension</i> , <b>2021</b> , 39, e10	1.9	
461	Safety and Tolerability of the Potassium Binder Patiromer From a Global Pharmacovigilance Database Collected Over 4 Years Compared with Data from the Clinical Trial Program. <i>Drugs - Real World Outcomes</i> , <b>2021</b> , 8, 315-323	2.2	4
460	Defining a minimal clinically meaningful difference in 12-month estimated glomerular filtration rate for clinical trials in deceased donor kidney transplantation. <i>Clinical Transplantation</i> , <b>2021</b> , 35, e14326	3.8	2
459	Patients and family members perspectives on arrhythmias and sudden death in dialysis: the HeartLink focus groups pilot study. <i>BMC Nephrology</i> , <b>2021</b> , 22, 199	2.7	0
458	Real-World Diagnosis and Treatment of Diabetic Kidney Disease. <i>Advances in Therapy</i> , <b>2021</b> , 38, 4425-4441	1.1	1

457	Clinical Management of Hyperkalemia. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 744-762	6.4	23
456	Adverse Health Outcomes Associated With Refractory and Treatment-Resistant Hypertension in the Chronic Renal Insufficiency Cohort. <i>Hypertension</i> , <b>2021</b> , 77, 72-81	8.5	6
455	Adherence to Healthy Dietary Patterns and Risk of CKD Progression and All-Cause Mortality: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study. <i>American Journal of Kidney Diseases</i> , <b>2021</b> , 77, 235-244	7.4	18
454	Characterization and implications of the initial estimated glomerular filtration rate @ipUpon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. <i>Kidney International</i> , <b>2021</b> , 99, 750-762	9.9	33
453	Risk Factors for CKD Progression: Overview of Findings from the CRIC Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2021</b> , 16, 648-659	6.9	16
452	A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2021</b> , 32, 469-478	12.7	1
451	The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , <b>2021</b> , 99, 34-47	9.9	42
450	Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. <i>CKJ: Clinical Kidney Journal</i> , <b>2021</b> , 14, 1396-1402	4.5	8
449	Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents. <i>American Journal of Nephrology</i> , <b>2021</b> , 52, 450-466	4.6	3
448	Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 35, 108029	3.2	2
447	Clinical Validation of an Immune Quiescence Gene Expression Signature in Kidney Transplantation.. <i>Kidney360</i> , <b>2021</b> , 2, 1998-2009	1.8	1
446	Renal Function Improvement Following ANG-3777 Treatment in Patients at High Risk for Delayed Graft Function After Kidney Transplantation. <i>Transplantation</i> , <b>2021</b> , 105, 443-450	1.8	4
445	Validation and clinical outcome in assessing donor-derived cell-free DNA monitoring insights of kidney allografts with longitudinal surveillance (ADMIRAL) study.. <i>Kidney International</i> , <b>2021</b> ,	9.9	2
444	Kidney function assessment and endpoint ascertainment in clinical trials.. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	6
443	Response to letter regarding article "Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease". <i>American Heart Journal</i> , <b>2020</b> , 223, 111-112	4.9	0
442	Anemia and Incident End-Stage Kidney Disease. <i>Kidney360</i> , <b>2020</b> , 1, 623-630	1.8	4
441	Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2836-2850	15.1	36
440	Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , <b>2020</b> , 97, 861-876	9.9	44

439	Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results. <i>American Journal of Nephrology</i> , <b>2020</b> , 51, 276-288	4.6	5
438	High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury. <i>American Journal of Transplantation</i> , <b>2020</b> , 20, 2491-2498	8.7	56
437	The REDUCE HTN: REINFORCE: Randomized, Sham-Controlled Trial of Bipolar Radiofrequency Renal Denervation for the Treatment of Hypertension. <i>JACC: Cardiovascular Interventions</i> , <b>2020</b> , 13, 461-470	5.470	23
436	The authors reply. <i>Kidney International</i> , <b>2020</b> , 97, 213-214	9.9	
435	Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease. <i>American Heart Journal</i> , <b>2020</b> , 223, 3-11	4.9	20
434	Association of Opioids and Nonsteroidal Anti-inflammatory Drugs With Outcomes in CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study. <i>American Journal of Kidney Diseases</i> , <b>2020</b> , 76, 184-193	7.4	20
433	132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects. <i>Diabetes</i> , <b>2020</b> , 69, 132-LB	0.9	
432	Apparent Treatment-Resistant Hypertension Assessed by Office and Ambulatory Blood Pressure in Chronic Kidney Disease-A Report from the Chronic Renal Insufficiency Cohort Study. <i>Kidney360</i> , <b>2020</b> , 1, 810-818	1.8	0
431	Systematic integrated analysis of genetic and epigenetic variation in diabetic kidney disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 29013-29024	11.5	11
430	Hematologic and Infectious Complications of Chronic Kidney Disease <b>2020</b> , 477-502		0
429	Long-term Kidney Transplantation Outcomes Network (APOLLO): Design and Rationale. <i>Kidney International Reports</i> , <b>2020</b> , 5, 278-288	4.1	27
428	Prognostic Significance of Ambulatory BP Monitoring in CKD: A Report from the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2020</b> , 31, 2609-2621	12.7	13
427	A prospective controlled study of metabolic and physiologic effects of kidney donation suggests that donors retain stable kidney function over the first nine years. <i>Kidney International</i> , <b>2020</b> , 98, 168-178	8.9	13
426	An evidence-based appraisal of complementary and alternative medicine strategies for the management of hypertension. <i>Journal of Hypertension</i> , <b>2020</b> , 38, 1412-1419	1.9	1
425	Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm.. <i>Kidney360</i> , <b>2020</b> , 1, 1148-1156	1.8	0
424	Donor-derived Cell-free DNA in Infections in Kidney Transplant Recipients: Case Series. <i>Transplantation Direct</i> , <b>2020</b> , 6, e568	2.3	9
423	Protein carbamylation and chronic kidney disease progression in the Chronic Renal Insufficiency Cohort Study. <i>Nephrology Dialysis Transplantation</i> , <b>2020</b> ,	4.3	5
422	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , <b>2020</b> , 97, 42-61	9.9	106

421	Association Between APOL1 Genotype and Need for Kidney Replacement Therapy in Patients Without Diabetes: Does Age Matter?. <i>American Journal of Kidney Diseases</i> , <b>2020</b> , 75, 294-296	7.4	1
420	Reserpine: A New Consideration of an Old Drug for Refractory Hypertension. <i>American Journal of Hypertension</i> , <b>2020</b> , 33, 708-710	2.3	1
419	Association of 24-Hour Ambulatory Blood Pressure Patterns with Cognitive Function and Physical Functioning in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2020</b> , 15, 455-464	6.9	2
418	Recognition and Management of a Less Common Cause of Chronic Kidney Disease: Autosomal Dominant Polycystic Kidney Disease. <i>Journal of Family Practice</i> , <b>2020</b> , 69, S57-S62	0.2	
417	Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD. <i>American Journal of Kidney Diseases</i> , <b>2019</b> , 74, 771-781	7.4	10
416	Self-Reported Incident Hypertension and Long-Term Kidney Function in Living Kidney Donors Compared with Healthy Nondonors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2019</b> , 14, 1493-1499	6.9	22
415	Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD. <i>American Journal of Kidney Diseases</i> , <b>2019</b> , 73, 827-836	7.4	25
414	Burden and Outcomes of Heart Failure Hospitalizations in Adults With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 2691-2700	15.1	28
413	Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment. <i>Postgraduate Medicine</i> , <b>2019</b> , 131, 367-375	3.7	2
412	Predicting, preventing, and managing cardiovascular and chronic kidney disease progression in people with type 2 diabetes: How to improve on traditional strategies. <i>Journal of Diabetes</i> , <b>2019</b> , 11, 619-622	3.8	3
411	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , <b>2019</b> , 95, 1304-1317	9.9	96
410	Magnitude of the Difference Between Clinic and Ambulatory Blood Pressures and Risk of Adverse Outcomes in Patients With Chronic Kidney Disease. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e011013	6	8
409	Analysis from the EMPA-REG OUTCOME trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. <i>Kidney International</i> , <b>2019</b> , 96, 489-504	9.9	47
408	Hypertension in CKD: Core Curriculum 2019. <i>American Journal of Kidney Diseases</i> , <b>2019</b> , 74, 120-131	7.4	120
407	KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline. <i>American Journal of Kidney Diseases</i> , <b>2019</b> , 73, 437-458	7.4	16
406	Metabolomic biomarkers are associated with mortality in patients with cirrhosis caused by primary biliary cholangitis or primary sclerosing cholangitis. <i>Future Science OA</i> , <b>2019</b> , 6, FSO441	2.7	2
405	Primary care of the kidney transplant recipient <b>2019</b> , 424-428		
404	Immunosuppression <b>2019</b> , 405-409		

403	Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial. <i>American Journal of Kidney Diseases</i> , <b>2019</b> , 73, 51-61	7.4	21
402	Epidemiology and Pathophysiology of Glomerular C4d Staining in Native Kidney Biopsies. <i>Kidney International Reports</i> , <b>2019</b> , 4, 1555-1567	4.1	17
401	Inflammation and Apparent Treatment-Resistant Hypertension in Patients With Chronic Kidney Disease. <i>Hypertension</i> , <b>2019</b> , 73, 785-793	8.5	18
400	Blood Pressure and Living Kidney Donors: A Clinical Perspective. <i>Transplantation Direct</i> , <b>2019</b> , 5, e488	2.3	5
399	Chronic Kidney Disease in the Primary Care Setting: Cardiovascular Disease Risk and Management. <i>Contemporary Cardiology</i> , <b>2019</b> , 179-216	0.1	
398	Risk of Ischemic Stroke in Patients Newly Diagnosed With Heart Failure: Focus on Patients Without Atrial Fibrillation. <i>Journal of Cardiac Failure</i> , <b>2019</b> , 25, 436-447	3.3	2
397	Calcium channel blockade and survival in recipients of successful renal transplant: an analysis of the FAVORIT trial results. <i>International Journal of Nephrology and Renovascular Disease</i> , <b>2018</b> , 11, 1-7	2.5	3
396	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>European Heart Journal</i> , <b>2018</b> , 39, 2314-2325	9.5	104
395	Central Blood Pressure and Cardiovascular Outcomes in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2018</b> , 13, 585-595	6.9	11
394	Hyperkalemia in the Hypertensive Patient. <i>Current Cardiology Reports</i> , <b>2018</b> , 20, 12	4.2	4
393	Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 665-675	4	17
392	Association of Pulse Wave Velocity With Chronic Kidney Disease Progression and Mortality: Findings From the CRIC Study (Chronic Renal Insufficiency Cohort). <i>Hypertension</i> , <b>2018</b> , 71, 1101-1107	8.5	62
391	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 1379-1390	15.1	43
390	Habitual sleep and kidney function in chronic kidney disease: the Chronic Renal Insufficiency Cohort study. <i>Journal of Sleep Research</i> , <b>2018</b> , 27, 281-289	5.8	15
389	Infection and Malignancy Outweigh Cardiovascular Mortality in Kidney Transplant Recipients: Post Hoc Analysis of the FAVORIT Trial. <i>American Journal of Medicine</i> , <b>2018</b> , 131, 165-172	2.4	22
388	The Reply. <i>American Journal of Medicine</i> , <b>2018</b> , 131, e349-e351	2.4	0
387	Effectiveness of informational decision aids and a live donor financial assistance program on pursuit of live kidney transplants in African American hemodialysis patients. <i>BMC Nephrology</i> , <b>2018</b> , 19, 107	2.7	15
386	Smoking and outcomes in kidney transplant recipients: a post hoc survival analysis of the FAVORIT trial. <i>International Journal of Nephrology and Renovascular Disease</i> , <b>2018</b> , 11, 155-164	2.5	13



385	Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function?. <i>Clinical Nephrology</i> , <b>2018</b> , 89, 314-329	2.1	11
384	Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors. <i>American Journal of Medicine</i> , <b>2018</b> , 131, 555-564.e3	2.4	29
383	Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis. <i>Translational Research</i> , <b>2018</b> , 195, 25-47	11	18
382	Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non-Vitamin K Antagonist Oral Anticoagulants. <i>Mayo Clinic Proceedings</i> , <b>2018</b> , 93, 1503-1519	6.4	7
381	Diabetic nephropathy after kidney transplantation in patients with pretransplantation type II diabetes: A retrospective case series study from a high-volume center in the United States. <i>Clinical Transplantation</i> , <b>2018</b> , 32, e13425	3.8	1
380	Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report. <i>American Journal of Kidney Diseases</i> , <b>2018</b> , 72, 873-884	7.4	35
379	Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. <i>ESC Heart Failure</i> , <b>2018</b> , 5, 592-602	3.7	30
378	Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial. <i>Transplantation</i> , <b>2017</b> , 101, 157-165	1.8	13
377	Evaluation and Management of Pulmonary Hypertension in Kidney Transplant Candidates and Recipients: Concepts and Controversies. <i>Transplantation</i> , <b>2017</b> , 101, 166-181	1.8	34
376	Cell-Free DNA and Active Rejection in Kidney Allografts. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2017</b> , 28, 2221-2232	12.7	241
375	Acute changes in glomerular filtration rate with renin-angiotensin system (RAS) inhibition: clinical implications. <i>Kidney International</i> , <b>2017</b> , 91, 529-531	9.9	13
374	Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2017</b> , 22, 434-446	2.6	22
373	Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence. <i>Current Medical Research and Opinion</i> , <b>2017</b> , 33, 1891-1900	2.5	17
372	Design of the Magnetic Resonance Imaging Evaluation of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (MAGMA) Trial. <i>Clinical Cardiology</i> , <b>2017</b> , 40, 633-640	3.3	6
371	Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , <b>2017</b> , 70, 337-346	7.4	31
370	A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease. <i>American Journal of Nephrology</i> , <b>2017</b> , 46, 364-370	4.6	7
369	The Author Replies. <i>Kidney International</i> , <b>2017</b> , 92, 1016-1017	9.9	
368	Inhibition of the Renin-Angiotensin System: How Far Have We Come? <b>2017</b> , 77-95		

367	Patiromer Lowers Serum Potassium When Taken without Food: Comparison to Dosing with Food from an Open-Label, Randomized, Parallel Group Hyperkalemia Study. <i>American Journal of Nephrology</i> , <b>2017</b> , 46, 323-332	4.6	23
366	Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2017</b> , 23, S2-S9	1.9	8
365	Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2017</b> , 23, S10-S19	1.9	15
364	The Association of Sleep Duration and Quality with CKD Progression. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2017</b> , 28, 3708-3715	12.7	35
363	Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study. <i>American Journal of Kidney Diseases</i> , <b>2017</b> , 70, 762-769	7.4	15
362	Association of QT-Prolonging Medication Use in CKD with Electrocardiographic Manifestations. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2017</b> , 12, 1409-1417	6.9	12
361	Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics. <i>Journal of Hypertension</i> , <b>2017</b> , 35 Suppl 1, S57-S63	1.9	18
360	Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial. <i>International Journal of Nephrology and Renovascular Disease</i> , <b>2017</b> , 10, 233-242	2.5	3
359	Urinary Sodium and Potassium Excretion and CKD Progression. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2016</b> , 27, 1202-12	12.7	120
358	Estimation of Glomerular Filtration Rate in Patients With Cirrhosis by Using New and Conventional Filtration Markers and Dimethylarginines. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 624-632.e2	6.9	16
357	Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis. <i>American Journal of Nephrology</i> , <b>2016</b> , 43, 229-36	4.6	91
356	Effect of Patiromer on Urinary Ion Excretion in Healthy Adults. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2016</b> , 11, 1769-1776	6.9	31
355	OS 19-04 CHRONIC DIURETIC THERAPY DOES NOT IMPAIR THE EFFECTIVENESS OF PATIROMER IN HYPERKALEMIC PATIENTS WITH CKD. <i>Journal of Hypertension</i> , <b>2016</b> , 34, e229	1.9	
354	Rivaroxaban in Chronic Hemodialysis Patients: Clarification of an Editorial Error. <i>American Journal of Nephrology</i> , <b>2016</b> , 44, 169	4.6	
353	Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. <i>Kidney International</i> , <b>2016</b> , 90, 696-704	9.9	40
352	Prevalence, Severity, and Impact of Renal Dysfunction in Acute Liver Failure on the US Liver Transplant Waiting List. <i>Digestive Diseases and Sciences</i> , <b>2016</b> , 61, 309-16	4	14
351	Current and future treatment options for managing hyperkalemia. <i>Kidney International Supplements</i> , <b>2016</b> , 6, 29-34	6.3	9
350	Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies. <i>Canadian Journal of Diabetes</i> , <b>2016</b> , 40, 247-57	2.1	12



349	Noteworthy observations in hypertension from 2015. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2016</b> , 25, 1-2	3.5	
348	The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors. <i>Postgraduate Medicine</i> , <b>2016</b> , 128, 290-8	3.7	18
347	Masked Hypertension and Elevated Nighttime Blood Pressure in CKD: Prevalence and Association with Target Organ Damage. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2016</b> , 11, 642-52	6.9	121
346	Human GRK4 $\Delta$ 42V Variant Promotes Angiotensin II Type I Receptor-Mediated Hypertension via Renal Histone Deacetylase Type 1 Inhibition. <i>Hypertension</i> , <b>2016</b> , 67, 325-34	8.5	20
345	Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study. <i>Hypertension</i> , <b>2016</b> , 67, 387-96	8.5	89
344	Early Kidney Allograft Dysfunction (Threatened Allograft): Comparative Effectiveness of Continuing Versus Discontinuation of Tacrolimus and Use of Sirolimus to Prevent Graft Failure: A Retrospective Patient-Centered Outcome Study. <i>Transplantation Direct</i> , <b>2016</b> , 2, e98	2.3	
343	Abnormalities in biomarkers of mineral and bone metabolism in kidney donors. <i>Kidney International</i> , <b>2016</b> , 90, 861-8	9.9	14
342	Live Donor Renal Transplant With Simultaneous Bilateral Nephrectomy for Autosomal Dominant Polycystic Kidney Disease Is Feasible and Satisfactory at Long-term Follow-up. <i>Transplantation</i> , <b>2016</b> , 100, 407-15	1.8	18
341	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. <i>Endocrine Practice</i> , <b>2016</b> , 22, 753-62	3.2	186
340	Late intervention with the small molecule BB3 mitigates postischemic kidney injury. <i>American Journal of Physiology - Renal Physiology</i> , <b>2016</b> , 311, F352-61	4.3	12
339	OS 19-03 TREATMENT WITH PATIROMER RESULTED IN DECREASES IN ALDOSTERONE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERKALEMIA ON RAAS INHIBITORS. <i>Journal of Hypertension</i> , <b>2016</b> , 34, e228-e229	1.9	
338	Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney. <i>Journal of Diabetes and Its Complications</i> , <b>2016</b> , 30, 1162-6	3.2	23
337	A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. <i>Transplantation</i> , <b>2016</b> , 100, 184-93	1.8	76
336	Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort. <i>Kidney International Reports</i> , <b>2016</b> , 1, 256-268	4.1	50
335	Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in CKD. <i>American Journal of Kidney Diseases</i> , <b>2016</b> , 68, 892-900	7.4	53
334	Response to: Hyperkalaemia in heart failure: binding the patient to improved treatment?. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 216	12.3	1
333	Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. <i>Journal of Clinical Hypertension</i> , <b>2016</b> , 18, 299-307	2.3	20
332	CCR2 inhibition: a panacea for diabetic kidney disease?. <i>Lancet Diabetes and Endocrinology</i> , <b>2015</b> , 3, 666-7	18.1	5

331	Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 314, 151-61	27.4	260
330	New agents for hyperkalemia. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1570-1	59.2	2
329	Clinical perspectives on the rationale for potassium supplementation. <i>Postgraduate Medicine</i> , <b>2015</b> , 127, 539-48	3.7	19
328	A prospective controlled study of living kidney donors: three-year follow-up. <i>American Journal of Kidney Diseases</i> , <b>2015</b> , 66, 114-24	7.4	112
327	Pharmacokinetics and Tolerability of Intravenous Sildenafil in Two Subjects with Child-Turcotte-Pugh Class C Cirrhosis and Renal Dysfunction. <i>Digestive Diseases and Sciences</i> , <b>2015</b> , 60, 3491-4	4	0
326	Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. <i>Kidney International</i> , <b>2015</b> , 88, 1427-1433	9.9	66
325	Diabetic nephropathy: Nonsteroidal MRA added to RAS blockade reduces albuminuria. <i>Nature Reviews Nephrology</i> , <b>2015</b> , 11, 691-2	14.9	1
324	The authors reply. <i>Kidney International</i> , <b>2015</b> , 87, 863-4	9.9	
323	The Evaluation and Therapeutic Management of Hypertension in the Transplant Patient. <i>Current Cardiology Reports</i> , <b>2015</b> , 17, 95	4.2	5
322	Patiromer lowers serum potassium and prevents recurrent hyperkalemia in patients with heart failure and CKD when treated with RAAS inhibitors: Results from OPAL-HK. <i>Heart and Lung: Journal of Acute and Critical Care</i> , <b>2015</b> , 44, 550	2.6	2
321	Cardiovascular risk assessment in kidney transplantation. <i>Kidney International</i> , <b>2015</b> , 87, 527-34	9.9	50
320	Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 211-21	59.2	376
319	Hematologic Complications of Chronic Kidney Disease <b>2015</b> , 277-284		
318	Urine neutrophil gelatinase-associated lipocalin and risk of cardiovascular disease and death in CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , <b>2015</b> , 65, 267-74	7.4	49
317	Patiromer Reduces Serum K <sup>+</sup> in Hyperkalemic Patients with HF and CKD on RAAS Inhibitors: Results from OPAL-HK and AMETHYST-DN. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, S107-S108	3.3	4
316	Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1057-65	12.3	106
315	Safety events in kidney transplant recipients: results from the folic Acid for vascular outcome reduction in transplant trial. <i>Transplantation</i> , <b>2015</b> , 99, 1003-8	1.8	5
314	Is there an optimal strategy for pretransplant cardiovascular screening?. <i>Transplantation</i> , <b>2015</b> , 99, 656-71.8		1

313	Time-updated systolic blood pressure and the progression of chronic kidney disease: a cohort study. <i>Annals of Internal Medicine</i> , <b>2015</b> , 162, 258-65	8	87
312	Defining, Treating, and Understanding Chronic Kidney Disease--A Complex Disorder. <i>Journal of Clinical Hypertension</i> , <b>2015</b> , 17, 514-27	2.3	14
311	Novel RAAS agonists and antagonists: clinical applications and controversies. <i>Nature Reviews Endocrinology</i> , <b>2015</b> , 11, 242-52	15.2	94
310	Assessment and management of hypertension in transplant patients. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2015</b> , 26, 1248-60	12.7	103
309	Assessment and management of hypertension in patients on dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2014</b> , 25, 1630-46	12.7	106
308	A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements. <i>American Journal of Nephrology</i> , <b>2014</b> , 39, 543-52	4.6	21
307	Salt, hypertension, and proteinuria in diabetic nephropathy. <i>Lancet Diabetes and Endocrinology</i> , <b>2014</b> , 2, 351-2	18.1	4
306	In the clinic: hypertension. <i>Annals of Internal Medicine</i> , <b>2014</b> , 161, ITC1-15; quiz ITC16	8	20
305	Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. <i>Journal of Clinical Hypertension</i> , <b>2014</b> , 16, 875-82	2.3	74
304	Usability of mobile technology to screen for drug-drug interactions in kidney transplant patients. <i>American Journal of Nephrology</i> , <b>2014</b> , 40, 97-104	4.6	5
303	Hypertension and kidney disease. <i>Journal of the American Society of Hypertension</i> , <b>2014</b> , 8, 855-7; quiz 858-9		3
302	Treatment-resistant hypertension in the transplant recipient. <i>Seminars in Nephrology</i> , <b>2014</b> , 34, 560-70	4.8	11
301	Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. <i>Hepatology</i> , <b>2014</b> , 59, 1532-42	11.2	88
300	BP, cardiovascular disease, and death in the Folic Acid for Vascular Outcome Reduction in Transplantation trial. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2014</b> , 25, 1554-62	12.7	49
299	Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). <i>Current Medical Research and Opinion</i> , <b>2014</b> , 30, 1759-68	2.5	85
298	Safety of medical therapy in patients with chronic kidney disease and end-stage renal disease. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2014</b> , 23, 306-13	3.5	27
297	Specific management of anemia and hypertension in renal transplant recipients: influence of renin-angiotensin system blockade. <i>American Journal of Nephrology</i> , <b>2014</b> , 39, 1-7	4.6	13
296	The use of thiazides in chronic kidney disease. <i>Current Hypertension Reviews</i> , <b>2014</b> , 10, 81-5	2.3	2

295	Pharmacogenomics of G Protein-Coupled Receptor Signaling and Other Pathways in Essential Hypertension. <i>Methods in Pharmacology and Toxicology</i> , <b>2014</b> , 299-312	1.1	1
294	A prospective controlled study of kidney donors: baseline and 6-month follow-up. <i>American Journal of Kidney Diseases</i> , <b>2013</b> , 62, 577-86	7.4	258
293	Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. <i>American Journal of Medicine</i> , <b>2013</b> , 126, 501-8	2.4	40
292	Treated hypertension and the white coat phenomenon: Office readings are inadequate measures of efficacy. <i>Journal of the American Society of Hypertension</i> , <b>2013</b> , 7, 236-43		13
291	Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. <i>Lancet, The</i> , <b>2013</b> , 381, 537-45	4.0	109
290	Lower Blood Pressure (BP) with Canagliflozin (CANA) in Subjects with Type 2 Diabetes Mellitus (T2DM). <i>Canadian Journal of Diabetes</i> , <b>2013</b> , 37, S3	2.1	2
289	Obesity, blood pressure, and cardiovascular outcomes - AuthorsReply. <i>Lancet, The</i> , <b>2013</b> , 381, 1982-3	4.0	
288	KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. <i>American Journal of Kidney Diseases</i> , <b>2013</b> , 62, 201-13	7.4	133
287	Efficacy of amlodipine/olmesartan medoxomil $\oplus$ hydrochlorothiazide in patients aged $\geq 65$ or Postgraduate Medicine, <b>2013</b> , 125, 124-34	3.7	4
286	Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis. <i>American Journal of Nephrology</i> , <b>2013</b> , 38, 345-54	4.6	25
285	Antibody-mediated allograft rejection: morphologic spectrum and serologic correlations in surveillance and for cause biopsies. <i>Transplantation</i> , <b>2013</b> , 95, 128-36	1.8	39
284	Blood pressure response with fixed-dose combination therapy: comparing hydrochlorothiazide with amlodipine through individual-level meta-analysis. <i>Journal of Hypertension</i> , <b>2013</b> , 31, 1692-701	1.9	6
283	Benefits Improvement and Protection Act $\text{\textcircled{C}}$ impact on transplantation rates among elderly MEDICARE beneficiaries with end-stage renal disease. <i>Transplantation</i> , <b>2013</b> , 95, 463-9	1.8	
282	Eosinophilia as an early indicator of pancreatic allograft rejection. <i>Clinical Transplantation</i> , <b>2012</b> , 26, 238-43		8
281	Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the FAVORIT study. <i>Clinical Transplantation</i> , <b>2012</b> , 26, E438-46	3.8	41
280	Estimating GFR among participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , <b>2012</b> , 60, 250-61	7.4	154
279	Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. <i>Cardiovascular Therapeutics</i> , <b>2012</b> , 30, 342-50	3.3	18
278	Debate from the 2012 ASH Annual Scientific Sessions: should blood pressure be reduced in hemodialysis patients? Con position. <i>Journal of the American Society of Hypertension</i> , <b>2012</b> , 6, 443-7		5

277	Plant protein intake is associated with fibroblast growth factor 23 and serum bicarbonate levels in patients with chronic kidney disease: the Chronic Renal Insufficiency Cohort study. <i>Journal of Renal Nutrition</i> , <b>2012</b> , 22, 379-388.e1	3	66
276	Role of dietary therapies in the prevention and treatment of hypertension. <i>Nature Reviews Nephrology</i> , <b>2012</b> , 8, 413-22	14.9	8
275	Thiazide and thiazide-like diuretics: an opportunity to reduce blood pressure in patients with advanced kidney disease. <i>Current Hypertension Reports</i> , <b>2012</b> , 14, 416-20	4.7	16
274	Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 60, 434-80	15.1	253
273	Influence of creatinine versus glomerular filtration rate on non-steroidal anti-inflammatory drug prescriptions in chronic kidney disease. <i>American Journal of Nephrology</i> , <b>2012</b> , 36, 19-26	4.6	16
272	Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation: endorsed by the American Society of Transplant Surgeons, American Society of Transplantation, and National Kidney Foundation. <i>Circulation</i> , <b>2012</b> , 126, 117-18	16.7	181
271	Renal outcomes in hypertensive Black patients at high cardiovascular risk. <i>Kidney International</i> , <b>2012</b> , 81, 568-76	9.9	26
270	Genotype-based changes in serum uric acid affect blood pressure. <i>Kidney International</i> , <b>2012</b> , 81, 502-7	9.9	62
269	The role of ARBs alone or with HCTZ in the treatment of hypertension and prevention of cardiovascular and renal complications. <i>Postgraduate Medicine</i> , <b>2012</b> , 124, 40-52	3.7	9
268	Urinary sodium is a potent correlate of proteinuria: lessons from the chronic renal insufficiency cohort study. <i>American Journal of Nephrology</i> , <b>2012</b> , 36, 397-404	4.6	8
267	A qualitative study to identify reasons for discharges against medical advice in the cardiovascular setting. <i>BMJ Open</i> , <b>2012</b> , 2,	3	14
266	Anemia after kidney transplantation; its prevalence, risk factors, and independent association with graft and patient survival: a time-varying analysis. <i>Transplantation</i> , <b>2012</b> , 93, 923-8	1.8	36
265	A 72-year-old woman with several months of weight loss and generalized weakness. <i>American Journal of the Medical Sciences</i> , <b>2012</b> , 344, 142-5	2.2	
264	Antihypertensive Drugs <b>2012</b> , 1824-1878		1
263	Dual Blockade of the Renin-Angiotensin-Aldosterone System: Benefits Versus Adverse Outcomes <b>2012</b> , 453-465		
262	Acute fall in glomerular filtration rate with renin-angiotensin system inhibition: a biomeasure of therapeutic success?. <i>Kidney International</i> , <b>2011</b> , 80, 235-7	9.9	12
261	Management of hypertension in the transplant patient. <i>Journal of the American Society of Hypertension</i> , <b>2011</b> , 5, 425-32		13
260	Readmissions after unauthorized discharges in the cardiovascular setting. <i>Medical Care</i> , <b>2011</b> , 49, 215-24	5.1	9

259	Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients. <i>Journal of Hypertension</i> , <b>2011</b> , 29, 2031-7	1.9	1
258	A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil $\square$ hydrochlorothiazide. <i>Journal of Clinical Hypertension</i> , <b>2011</b> , 13, 404-12	2.3	62
257	Angiotensin-converting enzyme inhibitors. <i>Journal of Clinical Hypertension</i> , <b>2011</b> , 13, 667-75	2.3	70
256	Determinants of blood pressure response to low-salt intake in a healthy adult population. <i>Journal of Clinical Hypertension</i> , <b>2011</b> , 13, 795-800	2.3	17
255	Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. <i>Kidney International</i> , <b>2011</b> , 80, 288-94	9.9	45
254	Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. <i>Circulation</i> , <b>2011</b> , 123, 1763-70	16.7	140
253	A randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension. <i>Postgraduate Medicine</i> , <b>2011</b> , 123, 80-7	3.7	15
252	The role of angiotensin receptor blockers in diabetic nephropathy. <i>Postgraduate Medicine</i> , <b>2011</b> , 123, 109-21	3.7	9
251	Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. <i>Hypertension</i> , <b>2011</b> , 57, 174-9	8.5	48
250	Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials. <i>Circulation: Heart Failure</i> , <b>2011</b> , 4, 18-26	7.6	48
249	Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. <i>Kidney International</i> , <b>2011</b> , 79, 897-907	9.9	149
248	The evolving role of mTOR inhibition in transplantation tolerance. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2011</b> , 22, 408-15	12.7	42
247	Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2011</b> , 6, 2612-9	6.9	38
246	Acute kidney injury following cardiac surgery: role of perioperative blood pressure control. <i>American Journal of Nephrology</i> , <b>2011</b> , 33, 438-52	4.6	32
245	The Author Replies:. <i>Kidney International</i> , <b>2011</b> , 79, 1379-1380	9.9	
244	Short-term effects of vitamin D receptor activation on serum creatinine, creatinine generation, and glomerular filtration. <i>Kidney International</i> , <b>2011</b> , 80, 1016-7	9.9	4
243	Measured GFR does not outperform estimated GFR in predicting CKD-related complications. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2011</b> , 22, 1931-7	12.7	52
242	Hemodynamic correlates of proteinuria in chronic kidney disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2011</b> , 6, 2403-10	6.9	31



241	Telmisartan in incipient and overt diabetic renal disease. <i>Journal of Nephrology</i> , <b>2011</b> , 24, 263-73	4.8	8
240	Chronic Kidney Disease in the Primary Care Setting: Importance for Estimating Cardiovascular Disease Risk and Use of Appropriate Therapies <b>2011</b> , 165-183		
239	Recognizing the link between chronic kidney disease and cardiovascular disease. <i>American Journal of Managed Care</i> , <b>2011</b> , 17 Suppl 15, S396-402	2.1	9
238	mTOR inhibition: the learning curve in kidney transplantation. <i>Transplant International</i> , <b>2010</b> , 23, 447-60	3	23
237	Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2010</b> , 5, 1255-60	6.9	102
236	Aortic PWV in chronic kidney disease: a CRIC ancillary study. <i>American Journal of Hypertension</i> , <b>2010</b> , 23, 282-9	2.3	160
235	Acute kidney injury and cardiovascular outcomes in acute severe hypertension. <i>Circulation</i> , <b>2010</b> , 121, 2183-91	16.7	38
234	Reasons for discharges against medical advice: a qualitative study. <i>BMJ Quality and Safety</i> , <b>2010</b> , 19, 420-4	5.4	25
233	Relative plasma volume monitoring and blood pressure control: an overlooked opportunity to achieve dry weight in the hemodialysis patient. <i>Hypertension</i> , <b>2010</b> , 55, 226-7	8.5	4
232	Effects of high- and low-sodium diets on ambulatory blood pressure in patients with hypertension receiving aliskiren. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2010</b> , 15, 356-63	2.6	22
231	Hypervolemia and blood pressure: powerful indicators of increased mortality among hemodialysis patients. <i>Hypertension</i> , <b>2010</b> , 56, 341-3	8.5	10
230	Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2010</b> , 5, 531-48	6.9	146
229	Dietary fructose and elevated levels of blood pressure. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2010</b> , 21, 1416-8	12.7	1
228	Development and validation of GFR-estimating equations using diabetes, transplant and weight. <i>Nephrology Dialysis Transplantation</i> , <b>2010</b> , 25, 449-57	4.3	90
227	The death of John Paul Jones and resurrection as father of the US Navy <i>American Journal of Nephrology</i> , <b>2010</b> , 31, 90-4	4.6	1
226	Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?. <i>American Journal of Nephrology</i> , <b>2010</b> , 31, 469-70	4.6	20
225	Variability of creatinine measurements in clinical laboratories: results from the CRIC study. <i>American Journal of Nephrology</i> , <b>2010</b> , 31, 426-34	4.6	75
224	Have we fallen off target with concerns surrounding dual RAAS blockade?. <i>Kidney International</i> , <b>2010</b> , 78, 539-45	9.9	11

223	Cardiovascular events during differing hypertension therapies in patients with diabetes. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 56, 77-85	15.1	172
222	Cost-effectiveness of lower targets for blood pressure and low-density lipoprotein cholesterol in diabetes: the Stop Atherosclerosis in Native Diabetics Study (SANDS). <i>Journal of Clinical Lipidology</i> , <b>2010</b> , 4, 165-72	4.9	5
221	Achieving lipid targets in adults with type 2 diabetes: the Stop Atherosclerosis in Native Diabetics Study. <i>Journal of Clinical Lipidology</i> , <b>2010</b> , 4, 435-43	4.9	8
220	Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. <i>Lancet, The</i> , <b>2010</b> , 375, 1173-81	4.0	374
219	Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. <i>Journal of Hypertension</i> , <b>2010</b> , 28, 186-93	1.9	14
218	The independent association between serum uric acid and graft outcomes after kidney transplantation. <i>Transplantation</i> , <b>2010</b> , 89, 573-9	1.8	45
217	A study of renal outcomes in obese living kidney donors. <i>Transplantation</i> , <b>2010</b> , 90, 993-9	1.8	54
216	Renin inhibition and microalbuminuria development: meaningful predictor of kidney disease progression. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2010</b> , 19, 437-43	3.5	2
215	Does blockade of the Renin-Angiotensin-aldosterone system slow progression of all forms of kidney disease?. <i>Current Hypertension Reports</i> , <b>2010</b> , 12, 369-77	4.7	19
214	Optimal blood pressure for a patient with type 2 diabetes mellitus: insight from the ACCORD study. <i>Current Hypertension Reports</i> , <b>2010</b> , 12, 313-5	4.7	4
213	Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , <b>2010</b> , 55, 441-51	7.4	236
212	Cigarette smoking, kidney function, and mortality after live donor kidney transplant. <i>American Journal of Kidney Diseases</i> , <b>2010</b> , 55, 907-15	7.4	34
211	Pulsatile intermittent intravenous insulin therapy for attenuation of retinopathy and nephropathy in type 1 diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , <b>2010</b> , 59, 1429-34	12.7	9
210	Hypertension and the kidney: perspectives on the relationship of kidney disease and cardiovascular disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2009</b> , 4, 2045-50	6.9	17
209	Beta-blockers in the treatment of hypertension: are there clinically relevant differences?. <i>Postgraduate Medicine</i> , <b>2009</b> , 121, 90-8	3.7	22
208	The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease. <i>Postgraduate Medicine</i> , <b>2009</b> , 121, 96-103	3.7	12
207	The frequency of hyperkalemia and its significance in chronic kidney disease. <i>Archives of Internal Medicine</i> , <b>2009</b> , 169, 1156-62		381
206	Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. <i>European Journal of Heart Failure</i> , <b>2009</b> , 11, 542-50	12.3	12

205	The Obesity Paradox: Impact of Obesity on the Prevalence and Prognosis of Cardiovascular Diseases. <i>Postgraduate Medicine</i> , <b>2009</b> , 121, 164-165	3.7	
204	Optimal dietary strategies for reducing incident hypertension. <i>Hypertension</i> , <b>2009</b> , 54, 698-9	8.5	3
203	Assessing the blood pressure-lowering efficacy of antihypertensive medications: which blood pressures should we use?. <i>Journal of Clinical Hypertension</i> , <b>2009</b> , 11, 155-8	2.3	1
202	Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trial. <i>Journal of Clinical Hypertension</i> , <b>2009</b> , 11, 540-8	2.3	16
201	What is left ventricular hypertrophy and is there a reason to regress left ventricular hypertrophy?. <i>Journal of Clinical Hypertension</i> , <b>2009</b> , 11, 407-10	2.3	3
200	The impact of reduced immunosuppression on graft outcomes in elderly renal transplant recipients. <i>Clinical Transplantation</i> , <b>2009</b> , 23, 930-7	3.8	33
199	Prescribing trends and drug budget impact of the ARBs in the UK. <i>Value in Health</i> , <b>2009</b> , 12, 302-8	3.3	8
198	Gauging adequacy of cardiovascular disease treatment: importance of estimating glomerular filtration rate and time-varying albuminuria. <i>Journal of the American Society of Hypertension</i> , <b>2009</b> , 3, 277-85		1
197	Renin angiotensin system inhibition in the older person: a review. <i>Clinics in Geriatric Medicine</i> , <b>2009</b> , 25, 245-57	3.8	6
196	Drug interactions in transplant patients: what everyone should know. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2009</b> , 18, 404-11	3.5	49
195	A study of renal outcomes in African American living kidney donors. <i>Transplantation</i> , <b>2009</b> , 88, 1371-6	1.8	40
194	Predictors of compliance with antihypertensive therapy in a high-risk medicaid population. <i>Journal of the National Medical Association</i> , <b>2009</b> , 101, 34-9	2.3	57
193	Minimizing the risk of chronic allograft nephropathy. <i>Transplantation</i> , <b>2009</b> , 87, S14-8	1.8	17
192	Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. <i>Journal of Hypertension</i> , <b>2009</b> , 27, 886-93	1.9	31
191	Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , <b>2009</b> , 24, 919-25	4.3	33
190	MYH9 is associated with nondiabetic end-stage renal disease in African Americans. <i>Nature Genetics</i> , <b>2008</b> , 40, 1185-92	36.3	518
189	A single center comparison of long-term outcomes of renal allografts procured laparoscopically versus historic controls procured by the open approach. <i>Transplant International</i> , <b>2008</b> , 21, 908-14	3	8
188	Newer combination therapies in the management of hypertension: an update. <i>Journal of Clinical Hypertension</i> , <b>2008</b> , 10, 398-405	2.3	3

187	Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?. <i>Journal of Clinical Hypertension</i> , <b>2008</b> , 10, 146-52	2.3	18
186	Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 2198-205	15.1	208
185	The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study. <i>American Heart Journal</i> , <b>2008</b> , 155, 823-8	4.9	93
184	Risk-based classification of hypertension and the role of combination therapy. <i>Journal of Clinical Hypertension</i> , <b>2008</b> , 10, 4-12	2.3	18
183	Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial. <i>Clinical Therapeutics</i> , <b>2008</b> , 30, 2354-65	3.5	9
182	Is activated vitamin D supplementation renoprotective?. <i>Hypertension</i> , <b>2008</b> , 52, 211-2	8.5	6
181	Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2008</b> , 299, 1678-89	27.4	185
180	Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression. <i>Postgraduate Medicine</i> , <b>2008</b> , 120, 33-42	3.7	14
179	Renal function and cardiovascular response to mental stress. <i>American Journal of Nephrology</i> , <b>2008</b> , 28, 304-10	4.6	5
178	Genetic influences on blood pressure response to the cold pressor test: results from the Heredity and Phenotype Intervention Heart Study. <i>Journal of Hypertension</i> , <b>2008</b> , 26, 729-36	1.9	19
177	The balance of angiotensin II and nitric oxide in kidney diseases. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2008</b> , 17, 51-6	3.5	12
176	Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?. <i>Current Opinion in Organ Transplantation</i> , <b>2008</b> , 13, 614-21	2.5	18
175	Are we "ONTARGET" yet with regard to optimal antihypertensive regimens?. <i>Current Hypertension Reports</i> , <b>2008</b> , 10, 385-6	4.7	
174	Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in old order amish. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 2874-81		72
173	Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. <i>Kidney International</i> , <b>2008</b> , 74, 364-9	9.9	119
172	Clinical commentary: how to choose blood pressure goals and treatment: influence of estimated glomerular filtration rate and albuminuria. <i>Transactions of the American Clinical and Climatological Association</i> , <b>2008</b> , 119, 53-61; discussion 61-3	0.9	
171	Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. <i>Blood Pressure</i> , <b>2007</b> , 16, 13-9	1.7	59
170	Early steroid withdrawal in solitary pancreas transplantation results in equivalent graft and patient survival compared with maintenance steroid therapy. <i>Clinical Transplantation</i> , <b>2007</b> , 21, 491-7	3.8	16

169	Exercise-induced hypertension, endothelial dysfunction, and coronary artery disease in a marathon runner. <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 743-4	3	24
168	Direct renin inhibitors: where will they fit in for antihypertensive treatment?. <i>Current Hypertension Reports</i> , <b>2007</b> , 9, 389-91	4-7	
167	Calcium channel blockers: their pharmacologic and therapeutic role in hypertension. <i>American Journal of Cardiovascular Drugs</i> , <b>2007</b> , 7 Suppl 1, 5-15	4	7
166	Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2007</b> , 18, 1540-6	12.7	225
165	Microalbuminuria and cardiovascular disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2007</b> , 2, 581-90	6.9	220
164	Usefulness of ARBs and ACE inhibitors in the prevention of vascular dementia in the elderly. <i>The American Journal of Geriatric Cardiology</i> , <b>2007</b> , 16, 175-82		18
163	Albuminuria: pathophysiology, epidemiology and clinical relevance of an emerging marker for cardiovascular disease. <i>Future Cardiology</i> , <b>2007</b> , 3, 519-24	1.3	12
162	COX-2 inhibitors and cardiovascular risk. <i>Sub-Cellular Biochemistry</i> , <b>2007</b> , 42, 159-74	5.5	6
161	How do you define "hypertension" in a patient with type 1 diabetes?. <i>Hypertension</i> , <b>2007</b> , 49, 13-4	8.5	2
160	The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2007</b> , 2, 766-85	6.9	25
159	Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering?. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2007</b> , 16, 416-21	3.5	7
158	Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension. <i>Journal of Clinical Hypertension</i> , <b>2007</b> , 9, 103-12	2.3	19
157	The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk. <i>Journal of Clinical Hypertension</i> , <b>2007</b> , 9, 23-30	2.3	13
156	Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. <i>American Journal of Hypertension</i> , <b>2007</b> , 20, 807-15	2.3	40
155	Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?. <i>Clinical Therapeutics</i> , <b>2007</b> , 29, 1803-24	3.5	129
154	Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. <i>Journal of the American Society of Hypertension</i> , <b>2007</b> , 1, 264-77		78
153	Cigarette smoking and incident chronic kidney disease: a systematic review. <i>American Journal of Nephrology</i> , <b>2007</b> , 27, 342-51	4.6	41
152	Treatment of prehypertension: how soon is soon enough? What therapy should be used?. <i>Current Hypertension Reports</i> , <b>2006</b> , 8, 393-4	4.7	1

151	An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. <i>American Journal of Nephrology</i> , <b>2006</b> , 26, 268-75	4.6	84
150	Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes--the Stop Atherosclerosis in Native Diabetics Study (SANDS). <i>American Heart Journal</i> , <b>2006</b> , 152, 867-75	4.9	23
149	Providing end-organ protection with renin-angiotensin system inhibition: the evidence so far. <i>Journal of Clinical Hypertension</i> , <b>2006</b> , 8, 99-105; quiz 106-7	2.3	14
148	Cyclosporine reduction causes decreasing of angiotensin II and transforming growth factor-beta expression in chronic allograft nephropathy. <i>Journal of Cardiothoracic-Renal Research</i> , <b>2006</b> , 1, 81-88		0
147	The metabolic syndrome: a call to action. <i>Coronary Artery Disease</i> , <b>2006</b> , 17, 77-80	1.4	30
146	Blood pressure salt sensitivity: a biomeasure of kidney disease susceptibility in diabetics?. <i>Nephrology Dialysis Transplantation</i> , <b>2005</b> , 20, 2022-4	4.3	2
145	The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease. <i>American Journal of Hypertension</i> , <b>2005</b> , 18, 100S-105S	2.3	17
144	Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 45, 1051-60 <sup>15.1</sup>		179
143	Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. <i>Archives of Internal Medicine</i> , <b>2005</b> , 165, 181-6		48
142	Salt intake and progression of chronic kidney disease: an overlooked modifiable exposure? A commentary. <i>American Journal of Kidney Diseases</i> , <b>2005</b> , 45, 176-88	7.4	67
141	Current status of kidney and pancreas transplantation in the United States, 1994-2003. <i>American Journal of Transplantation</i> , <b>2005</b> , 5, 904-15	8.7	118
140	Does dietary salt increase the risk for progression of kidney disease?. <i>Current Hypertension Reports</i> , <b>2005</b> , 7, 385-91	4.7	16
139	Reduction in microalbuminuria: a biomeasure of therapeutic success?. <i>Hypertension</i> , <b>2005</b> , 45, 181-2	8.5	7
138	A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. <i>Hypertension</i> , <b>2005</b> , 46, 508-13	8.5	31
137	Diabetes Mellitus and the Cardiovascular Metabolic Syndrome: Reducing Cardiovascular and Renal Events <b>2005</b> , 543-556		
136	Renal Protection in Chronic Kidney Disease <b>2005</b> , 281-294		1
135	Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. <i>American Journal of Nephrology</i> , <b>2004</b> , 24, 379-86	4.6	53
134	Differential effects of calcium antagonist subclasses on markers of nephropathy progression. <i>Kidney International</i> , <b>2004</b> , 65, 1991-2002	9.9	156



133	Albuminuria predicting outcome in diabetes: incidence of microalbuminuria in Asia-Pacific Rim. <i>Kidney International</i> , <b>2004</b> , S38-9	9.9	24
132	Clinical trials report. Adverse prognostic significance of new diabetes in treated hypertensive subjects. <i>Current Hypertension Reports</i> , <b>2004</b> , 6, 365-6	4.7	3
131	The tissue renin-angiotensin-aldosterone system in diabetes mellitus. <i>Current Hypertension Reports</i> , <b>2004</b> , 6, 98-105	4.7	20
130	Blood pressure management in the kidney transplant recipient. <i>Advances in Chronic Kidney Disease</i> , <b>2004</b> , 11, 172-83	4.7	19
129	Pharmacological strategies for kidney function preservation: are there differences by ethnicity?. <i>Advances in Chronic Kidney Disease</i> , <b>2004</b> , 11, 24-40		10
128	Microalbuminuria in type 2 diabetics: an important, overlooked cardiovascular risk factor. <i>Journal of Clinical Hypertension</i> , <b>2004</b> , 6, 134-41; quiz 142-3	2.3	45
127	Healthy diet and blood pressure. <i>Journal of Clinical Hypertension</i> , <b>2004</b> , 6, 381-2	2.3	
126	Dietary salt, blood pressure, and microalbuminuria. <i>Journal of Clinical Hypertension</i> , <b>2004</b> , 6, 23-6	2.3	10
125	Angiotensin II receptor blockers: the importance of dose in cardiovascular and renal risk reduction. <i>Journal of Clinical Hypertension</i> , <b>2004</b> , 6, 315-23; quiz 324-5	2.3	4
124	Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. <i>Transplantation</i> , <b>2004</b> , 77, 422-5	1.8	24
123	Retransplantation in patients with graft loss caused by polyoma virus nephropathy. <i>Transplantation</i> , <b>2004</b> , 77, 131-3	1.8	74
122	BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. <i>Transplantation</i> , <b>2004</b> , 78, 1069-73	1.8	58
121	Polyomavirus reactivation in native kidneys of pancreas alone allograft recipients. <i>Transplantation</i> , <b>2003</b> , 75, 1186-90	1.8	39
120	Clinical trials report. Chronic kidney disease: blood pressure, treatment goals, and cardiovascular outcomes. <i>Current Hypertension Reports</i> , <b>2003</b> , 5, 405-7	4.7	1
119	RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. <i>Current Hypertension Reports</i> , <b>2003</b> , 5, 408-17	4.7	54
118	Histological grading of chronic pancreas allograft rejection/graft sclerosis. <i>American Journal of Transplantation</i> , <b>2003</b> , 3, 599-605	8.7	36
117	Preemptive renal transplantation: why not?. <i>American Journal of Transplantation</i> , <b>2003</b> , 3, 1336-40	8.7	46
116	Coxibs--beyond the GI tract: renal and cardiovascular issues. <i>Journal of Pain and Symptom Management</i> , <b>2003</b> , 25, S41-9	4.8	31

115	Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. <i>American Heart Journal</i> , <b>2003</b> , 146, 591-604	4.9	100
114	Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. <i>Journal of Clinical Hypertension</i> , <b>2003</b> , 5, 202-9	2.3	72
113	Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. <i>Journal of Clinical Hypertension</i> , <b>2003</b> , 5, 330-5	2.3	58
112	Optimizing target-organ protection in patients with diabetes mellitus: angiotensin-converting enzyme inhibitors or angiotensin receptor blockers?. <i>Current Hypertension Reports</i> , <b>2003</b> , 5, 192-8	4.7	0
111	Is chronic calcineurin inhibitor toxicity responsible for long-term deterioration of renal function in transplant recipients?. <i>Transplantation Reviews</i> , <b>2003</b> , 17, 20-30	3.3	3
110	Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. <i>Archives of Internal Medicine</i> , <b>2003</b> , 163, 1555-65		315
109	Antihypertensive therapy: Progression of Renal Injury <b>2003</b> , 209-240		
108	Optimal strategies for modeling the reciprocal of creatinine versus time in renal transplant recipients and patients with native chronic renal disease. <i>American Journal of Kidney Diseases</i> , <b>2002</b> , 39, 753-61	7.4	6
107	Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: a pilot case-control study. <i>American Journal of Kidney Diseases</i> , <b>2002</b> , 39, 1096-101	7.4	37
106	Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers. <i>Current Hypertension Reports</i> , <b>2002</b> , 4, 333-5	4.7	2
105	Progressive renal and cardiovascular disease: optimal treatment strategies. <i>Kidney International</i> , <b>2002</b> , 62, 1482-92	9.9	10
104	Clinical course of polyoma virus nephropathy in 67 renal transplant patients. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2002</b> , 13, 2145-51	12.7	357
103	Polyomavirus nephropathy in native kidneys of a solitary pancreas transplant recipient. <i>Transplantation</i> , <b>2002</b> , 73, 1350-3	1.8	58
102	ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence. <i>Journal of Clinical Hypertension</i> , <b>2002</b> , 4, 420-3	2.3	21
101	Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. <i>American Journal of Hypertension</i> , <b>2002</b> , 15, 550-6	2.3	41
100	Current perspective on the cardiovascular effects of coxibs. <i>Cleveland Clinic Journal of Medicine</i> , <b>2002</b> , 69 Suppl 1, S147-52	2.8	6
99	Renal effects of nonselective NSAIDs and coxibs. <i>Cleveland Clinic Journal of Medicine</i> , <b>2002</b> , 69 Suppl 1, S153-8	2.8	54
98	Pancreas allograft biopsy: safety of percutaneous biopsy-results of a large experience. <i>Transplantation</i> , <b>2002</b> , 73, 553-5	1.8	68

97	Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. <i>Kidney International</i> , <b>2001</b> , 59, 1567-73	9.9	147
96	Use of angiotensin II receptor blockers alone and in combination with other drugs: a large clinical experience trial. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , <b>2001</b> , 2, S217-S222	3	
95	The role of angiotensin II and TGF-beta on the progression of chronic allograft nephropathy. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , <b>2001</b> , 2, S188-S190	3	2
94	The beta blockers: are they as protective in hypertension as in other cardiovascular conditions?. <i>Journal of Clinical Hypertension</i> , <b>2001</b> , 3, 236-43	2.3	8
93	Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. <i>Circulation</i> , <b>2001</b> , 104, 2280-8	16.7	274
92	Hypertension in patients with type 2 diabetes. <i>Hospital Practice (1995)</i> , <b>2001</b> , 36, 41-2, 47-8, 51-4; discussion 54	2.2	
91	Appropriate use of calcium antagonists in hypertension. <i>Hospital Practice (1995)</i> , <b>2001</b> , 36, 47-8, 53-5	2.2	
90	The inevitability of renal function loss in patients with hypercreatinemia. <i>American Journal of Nephrology</i> , <b>2001</b> , 21, 386-9	4.6	3
89	Morphological Spectrum of Polyoma Virus Disease in Renal Allografts: Diagnostic Accuracy of Urine Cytology. <i>American Journal of Transplantation</i> , <b>2001</b> , 1, 373-381	8.7	136
88	Recipient outcome after receiving a laparoscopically harvested kidney from a living donor. <i>Transplantation</i> , <b>2001</b> , 72, 355-6	1.8	2
87	Implications of a health lifestyle and medication analysis for improving hypertension control. <i>Archives of Internal Medicine</i> , <b>2000</b> , 160, 481-90		74
86	Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2000</b> , 9, 403-11	3.5	27
85	The future of clinical trials in chronic renal disease: outcome of an NIH/FDA/Physician Specialist Conference. Evaluation of Clinical Trial Endpoints in Chronic Renal Disease Study Group. <i>Journal of Clinical Pharmacology</i> , <b>2000</b> , 40, 815-25	2.9	15
84	Preventing renal disease progression: is it the drug or the blood pressure reduction, or both?. <i>Current Hypertension Reports</i> , <b>2000</b> , 2, 497-9	4.7	2
83	Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?. <i>Archives of Internal Medicine</i> , <b>2000</b> , 160, 685-93		544
82	Diuretics and beta-blockers: is there a risk for dyslipidemia?. <i>American Heart Journal</i> , <b>2000</b> , 139, 174-83	4.9	44
81	Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy. <i>Metabolism: Clinical and Experimental</i> , <b>2000</b> , 49, 1491-5	12.7	21
80	Wednesday, may 17, broadway ballroom north, 3:00 pm to 5:00 pm. new blood pressure goals: Reality or fantasy-the importance of combination therapy: Achieving low blood pressure for the kidney: Is there really a problem?. <i>American Journal of Hypertension</i> , <b>2000</b> , 13, S329	2.3	

79	Effects of isradipine or enalapril on blood pressure in salt-sensitive hypertensives during low and high dietary salt intake. MIST II Trial Investigators. <i>American Journal of Hypertension</i> , <b>2000</b> , 13, 1180-8	2.3	26
78	The Role of Multiple Drug Therapy for Controlling Hypertension in African Americans. <i>Journal of Clinical Hypertension</i> , <b>2000</b> , 2, 99-108	2.3	1
77	The Effects of Candesartan Cilexetil in Isolated Systolic Hypertension: A Clinical Experience Trial. <i>Journal of Clinical Hypertension</i> , <b>2000</b> , 2, 181-186	2.3	5
76	Hypertensive cardiovascular disease in African Americans. <i>Current Hypertension Reports</i> , <b>1999</b> , 1, 521-8	4.7	26
75	Hypertension: goal systolic and diastolic blood pressure. <i>Current Hypertension Reports</i> , <b>1999</b> , 1, 411-3	4.7	
74	Risk for posttransplant Diabetes mellitus with current immunosuppressive medications. <i>American Journal of Kidney Diseases</i> , <b>1999</b> , 34, 1-13	7.4	302
73	Human polyoma virus in renal allograft biopsies: morphological findings and correlation with urine cytology. <i>Human Pathology</i> , <b>1999</b> , 30, 970-7	3.7	213
72	Indicators and treatment of hypertensive heart disease. <i>Hospital Practice (1995)</i> , <b>1999</b> , 34, 93-4, 99-100, 103-4 passim	2.2	
71	A comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. <i>Transplantation</i> , <b>1999</b> , 67, 722-8	1.8	184
70	Regulation of the epithelial cell-specific integrin, CD103, by human CD8+ cytolytic T lymphocytes. <i>Transplantation</i> , <b>1999</b> , 67, 1418-25	1.8	41
69	Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. <i>Transplantation</i> , <b>1999</b> , 68, 396-402	1.8	241
68	How Low Should We Treat Blood Pressure and Why?. <i>Journal of Clinical Hypertension</i> , <b>1999</b> , 1, 199-208	2.3	2
67	Efficacy of low-dose combination of bisoprolol/hydrochlorothiazide compared with amlodipine and enalapril in men and women with essential hypertension. <i>American Journal of Cardiology</i> , <b>1998</b> , 81, 1363-5	3.5	7
66	Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. <i>Kidney International</i> , <b>1998</b> , 54, 1283-9	9.9	200
65	Nocturnal reduction of blood pressure and the antihypertensive response to a diuretic or angiotensin converting enzyme inhibitor in obese hypertensive patients. TROPHY Study Group. <i>American Journal of Hypertension</i> , <b>1998</b> , 11, 914-20	2.3	36
64	The rationale for combination versus single-entity therapy in hypertension. <i>American Journal of Hypertension</i> , <b>1998</b> , 11, 163S-169S	2.3	19
63	Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. <i>Hypertension</i> , <b>1998</b> , 31, 1088-96	8.5	108
62	Impact of salt intake on blood pressure and proteinuria in diabetes: importance of the renin-angiotensin system. <i>Mineral and Electrolyte Metabolism</i> , <b>1998</b> , 24, 438-45		12

61	Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients. <i>Transplantation</i> , <b>1998</b> , 65, 242-8	1.8	34
60	Histologic grading of acute allograft rejection in pancreas needle biopsy: correlation to serum enzymes, glycemia, and response to immunosuppressive treatment. <i>Transplantation</i> , <b>1998</b> , 66, 1741-5	1.8	55
59	Effect of dietary sodium on insulin sensitivity in older, obese, sedentary hypertensives. <i>American Journal of Hypertension</i> , <b>1997</b> , 10, 964-70	2.3	7
58	Increased living donor volunteer rates with a formal recipient family education program. <i>American Journal of Kidney Diseases</i> , <b>1997</b> , 29, 739-45	7.4	69
57	The influence of dietary salt on the antiproteinuric effect of calcium channel blockers. <i>American Journal of Kidney Diseases</i> , <b>1997</b> , 29, 800-5	7.4	1
56	Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD. <i>Clinical Cardiology</i> , <b>1997</b> , 20, 562-8	3.3	12
55	Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. <i>Hypertension</i> , <b>1997</b> , 30, 140-5	8.5	118
54	Salt and blood pressure responses to calcium antagonism in hypertensive patients. <i>Hypertension</i> , <b>1997</b> , 30, 422-7	8.5	32
53	Safe pancreas transplantation in patients with coronary artery disease. <i>Transplantation</i> , <b>1997</b> , 63, 1294-9	1.8	21
52	Evaluation of pancreas transplant needle biopsy: reproducibility and revision of histologic grading system. <i>Transplantation</i> , <b>1997</b> , 63, 1579-86	1.8	100
51	A novel approach to the treatment of chronic allograft nephropathy. <i>Transplantation</i> , <b>1997</b> , 64, 1706-10	1.8	129
50	Hypertension in Elderly African-Americans. <i>The American Journal of Geriatric Cardiology</i> , <b>1997</b> , 6, 13-20		
49	Gender considerations in hypertension pathophysiology and treatment. <i>American Journal of Medicine</i> , <b>1996</b> , 101, 10S-21S	2.4	25
48	Therapeutic challenges in the obese diabetic patient with hypertension. <i>American Journal of Medicine</i> , <b>1996</b> , 101, 33S-46S	2.4	34
47	Double adult renal allografts: a technique for expansion of the cadaveric kidney donor pool. <i>Surgery</i> , <b>1996</b> , 120, 580-3; discussion 583-4	3.6	73
46	Pancreas transplantation for diabetes mellitus. <i>American Journal of Kidney Diseases</i> , <b>1996</b> , 27, 444-50	7.4	39
45	Significance of the Banff borderline biopsy. <i>American Journal of Kidney Diseases</i> , <b>1996</b> , 28, 585-8	7.4	65
44	Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. <i>Clinical Therapeutics</i> , <b>1996</b> , 18, 411-28	3.5	47

43	Insulin resistance, elevated glomerular filtration fraction, and renal injury. <i>Hypertension</i> , <b>1996</b> , 28, 127-32.	3.5	102
42	Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy. <i>Annals of Surgery</i> , <b>1996</b> , 224, 440-9; discussion 449-52	7.8	97
41	Isolated pancreas rejection in combined kidney pancreas transplantation. <i>Transplantation</i> , <b>1996</b> , 61, 974-7.	1.8	61
40	Late pancreas allograft rejection. Preliminary experience with factors predisposing to rejection. <i>Transplantation</i> , <b>1996</b> , 62, 539-43	1.8	7
39	Double renal allografts successfully increase utilization of kidneys from older donors within a single organ procurement organization. <i>Transplantation</i> , <b>1996</b> , 62, 1581-3	1.8	53
38	Histologic findings in islets of whole pancreas allografts: lack of evidence for recurrent cell-mediated diabetes mellitus. <i>Transplantation</i> , <b>1996</b> , 62, 1770-2	1.8	22
37	Salt intake and hypertensive renal injury in African-Americans. A therapeutic perspective. <i>American Journal of Hypertension</i> , <b>1995</b> , 8, 635-44	2.3	17
36	Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. <i>American Heart Journal</i> , <b>1995</b> , 130, 359-66	4.9	68
35	First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. <i>Journal of Clinical Pharmacology</i> , <b>1995</b> , 35, 182-8.	3.9	34
34	Hypertension in diabetic patients: an update of interventional studies to preserve renal function. <i>Journal of Clinical Pharmacology</i> , <b>1995</b> , 35, 73-80	2.9	9
33	Diltiazem: ten years of clinical experience in the treatment of hypertension. <i>Journal of Clinical Pharmacology</i> , <b>1995</b> , 35, 220-32	2.9	28
32	Salt-induced increases in systolic blood pressure affect renal hemodynamics and proteinuria. <i>Hypertension</i> , <b>1995</b> , 25, 1339-44	8.5	74
31	Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. <i>Hypertension</i> , <b>1995</b> , 26, 124-30	8.5	92
30	Supplementation of Immunosuppressive Regimens with Calcium Channel Blockers. <i>BioDrugs</i> , <b>1994</b> , 2, 458-467		4
29	VALUE OF IN VITRO CD4+ T HELPER CELL FUNCTION TEST FOR PREDICTING LONG-TERM LOSS OF HUMAN RENAL ALLOGRAFTS. <i>Transplantation</i> , <b>1994</b> , 57, 480-482	1.8	4
28	Renal adaptation to the failing heart. <i>Postgraduate Medicine</i> , <b>1994</b> , 95, 153-156	3.7	21
27	Essential hypertension in blacks: is it a metabolic disorder?. <i>American Journal of Kidney Diseases</i> , <b>1993</b> , 21, 58-67	7.4	5
26	Calcium channel blockers inhibit cellular uptake of thymidine, uridine and leucine: the incorporation of these molecules into DNA, RNA and protein in the presence of calcium channel blockers is not a valid measure of lymphocyte activation. <i>Immunopharmacology</i> , <b>1993</b> , 25, 75-82		10



25	Risk for renal injury in diabetic hypertensive patients. The physiologic basis for blood pressure control. <i>Postgraduate Medicine</i> , <b>1992</b> , 91, 77-80, 83-4	3.7	3
24	Risk for renal injury in diabetic hypertensive patients. Pharmacologic approaches. <i>Postgraduate Medicine</i> , <b>1992</b> , 91, 87-91, 94-5	3.7	1
23	Evidence that the antiproliferative effect of verapamil on afferent and efferent immune responses is independent of calcium channel inhibition. <i>Transplantation</i> , <b>1992</b> , 54, 681-5	1.8	18
22	A dose-response trial of once-daily diltiazem. <i>American Heart Journal</i> , <b>1992</b> , 123, 1022-6	4.9	28
21	Determinants of the renal response to ACE inhibition in patients with congestive heart failure. <i>American Heart Journal</i> , <b>1992</b> , 124, 131-6	4.9	13
20	Hypertensive nephropathy: is a more physiologic approach to blood pressure control an important concern for the preservation of renal function?. <i>American Journal of Medicine</i> , <b>1992</b> , 93, 27S-37S	2.4	10
19	Minimization of indomethacin-induced reduction in renal function by misoprostol. <i>Journal of Clinical Pharmacology</i> , <b>1991</b> , 31, 729-35	2.9	16
18	Correlation of in vitro CD4+ T helper cell function with clinical graft status in immunosuppressed kidney transplant recipients. <i>Transplantation</i> , <b>1991</b> , 52, 284-91	1.8	41
17	Additive inhibition of afferent and efferent immunological responses of human peripheral blood mononuclear cells by verapamil and cyclosporine. <i>Transplantation</i> , <b>1991</b> , 51, 851-7	1.8	17
16	Impact of age, race, and obesity on hypertensive mechanisms and therapy. <i>American Journal of Medicine</i> , <b>1991</b> , 90, 3S-14S	2.4	25
15	Therapeutic benefits of calcium channel blockers in cyclosporine-treated organ transplant recipients: blood pressure control and immunosuppression. <i>American Journal of Medicine</i> , <b>1991</b> , 90, 32S-36S	2.4	27
14	Acute effects of intravenous cyclosporine on blood pressure, renal hemodynamics, and urine prostaglandin production of healthy humans. <i>Transplantation</i> , <b>1990</b> , 49, 41-7	1.8	64
13	Evaluation of the clinical pharmacology of nilvadipine in patients with mild to moderate essential hypertension. <i>Journal of Clinical Pharmacology</i> , <b>1990</b> , 30, 425-37	2.9	4
12	Radix Tripterygium wilfordii--a Chinese herbal medicine with potent immunosuppressive properties. <i>Transplantation</i> , <b>1990</b> , 50, 82-6	1.8	33
11	Renal effects of angiotensin-converting enzyme inhibition in congestive heart failure. <i>American Journal of Cardiology</i> , <b>1990</b> , 66, 14D-20D; discussion 20D-21D	3	20
10	Preliminary observations of the acute effects of selective serum thromboxane inhibition and angiotensin converting enzyme inhibition on blood pressure and renal hemodynamics in hypertensive humans. <i>Journal of Clinical Pharmacology</i> , <b>1989</b> , 29, 1108-16	2.9	1
9	Renal allograft biopsy and conversion of cyclosporine to azathioprine. <i>Transplantation</i> , <b>1989</b> , 47, 223-9	1.8	11
8	Pharmacologic management of systemic hypertension in blacks. <i>American Journal of Cardiology</i> , <b>1988</b> , 61, 46H-52H	3	25

7	Physiologic and hemodynamic considerations in blood pressure control while maintaining organ perfusion. <i>American Journal of Cardiology</i> , <b>1988</b> , 61, 60H-66H	3	7
6	Incidence and morbidity of cytomegalovirus disease associated with a seronegative recipient receiving seropositive donor-specific transfusion and living-related donor transplantation. A multicenter evaluation. <i>Transplantation</i> , <b>1988</b> , 45, 111-6	1.8	20
5	Incidence of cytomegalovirus disease in cyclosporine-treated renal transplant recipients based on donor/recipient pretransplant immunity. <i>Transplantation</i> , <b>1987</b> , 43, 187-93	1.8	28
4	Sustained-release diltiazem compared with atenolol monotherapy for mild to moderate systemic hypertension. <i>American Journal of Cardiology</i> , <b>1987</b> , 60, 361-411	3	17
3	The prognostic value of the eosinophil in acute renal allograft rejection. <i>Transplantation</i> , <b>1986</b> , 41, 709-128		52
2	Reevaluation of T cell subset monitoring in cyclosporine-treated renal allograft recipients. <i>Transplantation</i> , <b>1985</b> , 40, 620-3	1.8	15
1	Enzyme-linked immunosorbent assay for serum renal tubular antigen in kidney transplant patients. <i>Transplantation</i> , <b>1985</b> , 40, 642-7	1.8	2